Pancreatic Cancer Research

ResearcherJesse Brown VA Medical CenterActive in the last 2 years

Ajay Nmn Rana

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0951-2566; OpenAlex author ID A5081839578; NIH RePORTER profile ID 1973958. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 8)
Trials
0
Grants
3
Labs led
1
Collaborators
19
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper, 1 grant · 2020: 1 paper · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 grants

Papers 10

  1. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer. Last author DOI 10.1016/bs.acr.2023.02.003↗
  2. XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Last author DOI 10.1073/pnas.2116764119↗
  3. Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer. Last author DOI 10.1073/pnas.2200143119↗
  4. Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. Last author DOI 10.3389/fonc.2022.806963↗
  5. Trials and tribulations of pancreatic cancer immunotherapy. Last author DOI 10.1016/j.canlet.2021.01.031↗
  6. Mixed Lineage Kinase 3 phosphorylates prolyl-isomerase PIN1 and potentiates GLI1 signaling in pancreatic cancer development. Last author DOI 10.1016/j.canlet.2021.04.015↗
  7. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Last author DOI 10.3389/fonc.2021.688377↗
  8. Updated risk factors to inform early pancreatic cancer screening and identify high risk patients. First author DOI 10.1016/j.canlet.2020.04.022↗
  9. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-18-0850↗
  10. KRAS G12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs. Co-author DOI 10.1038/s41598-018-30916-6↗

Grants 3

  1. Exploiting the Cross-talk between Neurotrophin Receptors and Mixed Lineage Kinases to Target Pancreatic Cancer. I01BX004903↗
  2. BLR&D Research Career Scientist Award Application IK6BX004855↗
  3. Targeting Mixed Lineage Kinase3-Hedgehog Axis in Pancreatic Cancer I01BX002703↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel R. Principe · 9 shared papers, 2018–2022 · strength 1.27
  2. Hidayatullah G. Munshi · 7 shared papers, 2018–2022 · strength 0.92
  3. Patrick W. Underwood · 4 shared papers, 2021–2022 · strength 0.59
  4. Sandeep Kumar · 4 shared papers, 2019–2022 · strength 0.51
  5. Jose Gilberto Trevino · 3 shared papers, 2021–2022 · strength 0.45
  6. Murray Korc · 2 shared papers, 2021 · strength 0.33
  7. Suneel Deepak Kamath · 2 shared papers, 2021–2022 · strength 0.30
  8. Paul J. Grippo · 3 shared papers, 2018–2021 · strength 0.27
  9. Thao D. Pham · 2 shared papers, 2022 · strength 0.27
  10. Sandeep Kumar · 1 shared paper, 2023 · strength 0.22
  11. Navin Viswakarma · 2 shared papers, 2019–2021 · strength 0.21
  12. Carolina Torres · 2 shared papers, 2018–2019 · strength 0.16
  13. Jose Trevino · 1 shared paper, 2022 · strength 0.14
  14. Dinesh Thummuri · 1 shared paper, 2022 · strength 0.13
  15. Daohong Zhou · 1 shared paper, 2022 · strength 0.13
  16. Pier Cristoforo Giulianotti · 1 shared paper, 2021 · strength 0.12
  17. Ajay V. Maker · 1 shared paper, 2018 · strength 0.07
  18. David W. Dawson · 1 shared paper, 2018 · strength 0.07
  19. Lawrence B. Schook · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.